Clinical Investigation of Metabolic and Renal Clearance Pathways Contributing to the Elimination of Fevipiprant Using Probenecid as Perpetrator-Reference-Cited by-同舟云学术

Clinical Investigation of Metabolic and Renal Clearance Pathways Contributing to the Elimination of Fevipiprant Using Probenecid as Perpetrator

Published:2021-02-25 Issue:5 Volume:49 Page:389-394
ISSN:0090-9556
Container-title:Drug Metabolism and Disposition
language:en
Short-container-title:Drug Metab Dispos

Author:

Weiss H. Markus,Langenickel Thomas,Cain Meredith,Kulkarni Swarupa,Shah Bharti,Vemula Janardhana,Rahmanzadeh Gholamreza,Poller Birk^ORCID

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmaceutical Science,Pharmacology

Reference21 articles.

1. The risk of mycobacterial infections associated with inhaled corticosteroid use

2. Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials;Brightling;Lancet Respir Med,2021

3. Center for Drug Evaluation and Research (CDER) (2020) In vitro drug interaction studies — cytochrome P450 enzyme- and transporter-mediated drug interactions guidance for industry, US Department of Health and Human Services. Office of Communications, Division of Drug Information Center for Drug Evaluation and Research Food and Drug Administration, Silver Spring, Maryland.

4. The prostaglandin D2 receptor 2 pathway in asthma: a key player in airway inflammation;Domingo;Respir Res,2018

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predicting routes of phase I and II metabolism based on quantum mechanics and machine learning;Xenobiotica;2023-11-15

2. The Vital Role Played by Deferiprone in the Transition of Thalassaemia from a Fatal to a Chronic Disease and Challenges in Its Repurposing for Use in Non-Iron-Loaded Diseases;Pharmaceuticals;2023-07-18

3. Construction and Evaluation of a Novel Organic Anion Transporter 1/3 CRISPR/Cas9 Double-Knockout Rat Model;Pharmaceutics;2022-10-27

4. Human Pharmacokinetics of LYS006, an Oral Leukotriene A4 Hydrolase Inhibitor Displaying Target-Mediated Drug Disposition;Drug Metabolism and Disposition;2022-10-04

5. Pharmacokinetics and Main Metabolites of Anwulignan in Mice;Frontiers in Pharmacology;2022-07-05